CD274 and neoplasm: ‘Histology‐independent population‐enriched’ trials continue to be used for early signal detection in rare molecular subsets in ‘phase Ic expansion’ trials, which are essentially multiple parallel tumor‐specific phase IIa trials (e.g. anti‐PDL1 for ∼40 patients of each tumor‐type of interest within a ‘phase I expansion’) (Figure 8).